ArticleAnnals of neurology2019
Peripheral immune biomarkers and neurodegenerative diseases: A prospective cohort study with 20 years of follow-up.
Article in Annals of neurology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 39 citations in OpenAlex.
- Serum ferritin, neutrophil-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio are associated with levodopa-induced dyskinesia severity in Parkinson's disease.BMC neurology · 2026Article
- Review
- Tracing neuroinflammation in neurodegeneration: insights from a scoping review on biofluid biomarkers.Brain communications · 2026Review
- Immunosenescence in aging and neurodegenerative diseases: evidence, key hallmarks, and therapeutic implications.Translational neurodegeneration · 2025Review
- Correlation of inflammatory markers with depression and sleep disorders accompanying the prodromal stage of Parkinson's disease.World journal of psychiatry · 2025Review
- Early detection of Parkinson's disease through multiplex blood and urine biomarkers prior to clinical diagnosis.NPJ Parkinson's disease · 2025Article
- Tofacitinib extends survival in a mouse model of ALS through NK cell-independent mechanisms.Frontiers in immunology · 2025Article
- Circulating Levels of T-Cell Traits and the Risk of Amyotrophic Lateral Sclerosis: A Mendelian Randomization Study.Molecular neurobiology · 2024Article
- Neuronal-enriched small extracellular vesicles trigger a PD-L1-mediated broad suppression of T cells in Parkinson's disease.iScience · 2024Article
- Article
- The value of routine blood work-up in clinical stratification and prognosis of patients with amyotrophic lateral sclerosis.Journal of neurology · 2024Article
- The diagnostic value of neutrophil to lymphocyte ratio, albumin to fibrinogen ratio, and lymphocyte to monocyte ratio in Parkinson's disease: a retrospective study.Frontiers in neurology · 2024Article
- Peripheral immunity and risk of incident brain disorders: a prospective cohort study of 161,968 participants.Translational psychiatry · 2023Article
- Systemic inflammation and subsequent risk of amyotrophic lateral sclerosis: Prospective cohort study.Brain, behavior, and immunity · 2023Article
- Systemic inflammation and subsequent risk of amyotrophic lateral sclerosis: prospective cohort study.medRxiv : the preprint server for health sciences · 2023Article
- Machine learning analysis of the UK Biobank reveals IGF-1 and inflammatory biomarkers predict Parkinson's disease risk.PloS one · 2023Article
- Changes of T lymphocyte subpopulations and their roles in predicting the risk of Parkinson's disease.Journal of neurology · 2022Article
- Peripheral Immune Cell Numbers and C-Reactive Protein in Parkinson's Disease: Results from a Population-Based Study.Journal of Parkinson's disease · 2022Article
- Neuroinflammation and Immune Changes in Prodromal Parkinson's Disease and Other Synucleinopathies.Journal of Parkinson's disease · 2022Review
- NK cells associate with ALS in a sex- and age-dependent manner.JCI insight · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveTo assess the associations of several blood immune biomarkers with the future risks of amyotrophic lateral sclerosis and Parkinson disease in a prospective cohort study with 20 years of follow-up.
methodsThe Swedish Apolipoprotein-Related Mortality Risk study is a longitudinal cohort study including 812,073 participants with repeated blood biomarker measurements between 1985 and 1996 and a follow-up until 2011. Using a Cox model, we first estimated hazard ratios of amyotrophic lateral sclerosis and Parkinson disease in relation to leukocytes, immunoglobulin G, haptoglobin, and uric acid. We further described the temporal changes of these biomarkers during the 20 years prior to the diagnosis of these diseases.
resultsA total of 585 incident cases of amyotrophic lateral sclerosis and 3,769 incident cases of Parkinson disease were identified during the follow-up. Increasing concentrations of leukocytes, haptoglobin, and uric acid were associated with a lower risk of Parkinson disease. No statistically significant association was, however, noted between the studied biomarkers and amyotrophic lateral sclerosis. Parkinson disease patients appeared to have lower levels of leukocytes and haptoglobin between 20 and 10 years before diagnosis and lower levels of uric acid during the 20 years before diagnosis, compared to controls, although statistically significant differences were only noted during parts of the respective time intervals after multivariable adjustment. No clear differences were noted between patients with amyotrophic lateral sclerosis and controls.
interpretationIf verified in studies of independent populations, our findings may suggest a different role of systemic inflammation on the risk of Parkinson disease compared to amyotrophic lateral sclerosis. ANN NEUROL 2019;86:913-926.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.